Cargando…
Expansion With IL-15 Increases Cytotoxicity of Vγ9Vδ2 T Cells and Is Associated With Higher Levels of Cytotoxic Molecules and T-bet
Cancer immunotherapy has shown great advances during recent years, but it has yet to reach its full potential in all cancer types. Adoptive cell therapy (ACT) is now an approved treatment option for certain hematological cancers and has also shown success for some solid cancers. Still, benefit and e...
Autores principales: | Aehnlich, Pia, Carnaz Simões, Ana Micaela, Skadborg, Signe Koggersbøl, Holmen Olofsson, Gitte, thor Straten, Per |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485111/ https://www.ncbi.nlm.nih.gov/pubmed/32983105 http://dx.doi.org/10.3389/fimmu.2020.01868 |
Ejemplares similares
-
Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens
por: Holmen Olofsson, Gitte, et al.
Publicado: (2021) -
Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model
por: Idorn, Manja, et al.
Publicado: (2018) -
Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?
por: Jensen, Agnete Witness Praest, et al.
Publicado: (2021) -
Combined killing of cancer cells and cross presentation of tumor antigen by Vγ9Vδ2 T cells
por: Olofsson, Gitte Holmen, et al.
Publicado: (2015) -
Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet's disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity
por: Accardo-Palumbo, Antonina, et al.
Publicado: (2010)